Page 1

ResMed For investors Amy Wakeham +1 858-836-5000 investorrelations@resmed.com For media Jayme Rubenstein +1 858-836-6798 news@resmed.com Note : A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO , October 28 , 2021 - ResMed Inc. ( NYSE : RMD , ASX : RMD ) , a world - leading digital health company , today announced results for its quarter ended September 30 , 2021 . ● ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2022 Year - over - year revenue grows 20 % , operating profit up 21 % , non - GAAP operating profit up 18 % First Quarter 2022 Highlights All comparisons are to the prior year period Revenue increased by 20 % to $ 904.0 million ; up 19 % on a constant currency basis Gross margin of 56.0 % ; non - GAAP gross margin contracted 270 bps to 57.2 % Income from operations increased 21 % ; non - GAAP operating profit up 18 % Diluted earnings per share of $ 1.39 ; non - GAAP diluted earnings per share of $ 1.51 ● " Our first - quarter results demonstrate strong performance across our business with double - digit growth in both top line and bottom - line metrics , driven by ongoing high demand for our sleep and respiratory care products , and steady growth across our software - as - a - service business , " said Mick Farrell , ResMed CEO . " It is through the extraordinary efforts of our global ResMed team that we were able to deliver products and solutions to our customers amid unprecedented supply chain challenges that continue to restrict access to critical electronic components . As we navigate supply limitations and are forced to allocate products , we continue to ensure priority for highest - acuity and highest - need patients first , as well as working with physicians , providers , and community systems to maintain a sustainable flow of medical devices and digital health solutions to patients who need care . " " Despite constantly evolving market dynamics , we continue to pivot to meet the needs of our stakeholders , driving sustainable long - term growth , and ensuring that we are investing strongly in medical device research and development , as well as digital health innovation that will unlock value for all of our customers . I'm incredibly proud of our global teams that are working with providers and physicians in the most unusual times across 140 countries , to get products directly into the hands of patients who need our solutions most . "